Logo image
Back
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
Journal article   Open access   Peer reviewed

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data

Vivian P Bykerk, Peter Nash, David Nicholls, Yoshiya Tanaka, Kevin Winthrop, Christina Popova, Nicola Tilt and Derek Haaland
Rheumatology and Therapy, Vol.10, pp.693-706
2023
DOI: https://doi.org/10.1007/s40744-023-00541-5
PMCID: PMC10140240
PMID: 36848009
pdf
s40744-023-00541-51.05 MBDownloadView
Published Version Open Access CC BY-NC V4.0
url
https://doi.org/10.1007/s40744-023-00541-5View
Published Version

Abstract

Durability Tumor necrosis factor inhibitors Certolizumab pegol Rheumatoid arthritis
Introduction: There is a paucity of data on how patient characteristics may affect the long-term durability of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA). This study therefore aimed to investigate CZP durability and reasons for discontinuation over 5 years between different subgroups of patients with RA. Methods: Data were pooled from 27 clinical trials in RA patients. Durability was defined as the percentage of patients randomized to CZP at baseline who were still on CZP treatment at a given timepoint. Post hoc analyses of clinical trial data on CZP durability and reasons for discontinuation among different patient subgroups were conducted using Kaplan–Meier curves and Cox proportional hazards modeling. Patient subgroups included: age (18– < 45/45– < 65/ ≥ 65 years), gender (male/female), prior tumor necrosis factor inhibitor (TNFi) use (yes/no), and disease duration (< 1/1– < 5/5– < 10/ ≥ 10 years). Results: Among 6927 patients, the durability of CZP was 39.7% at 5 years. Patients aged ≥ 65 years had a 33% greater risk of CZP discontinuation than patients 18– < 45 years (hazard ratio [95% confidence interval]: 1.33 [1.19–1.49]) and patients with prior TNFi use had a 24% greater risk of discontinuing CZP than patients without (1.24 [1.12–1.37]). Conversely, greater durability was observed among patients who had a baseline disease duration of ≥ 1 year. Durability did not differ in the gender subgroup. Of the 6927 patients, the most common reason for discontinuation was inadequate levels of efficacy (13.5%); followed by adverse events (11.9%); consent withdrawn (6.7%); lost to follow-up (1.8%); protocol violation (1.7%); other reasons (9.3%). Conclusions: CZP durability was comparable with durability data on other bDMARDs in RA patients. Patient characteristics that were associated with greater durability included younger age, TNFi-naïvety, and disease duration ≥ 1 year. Findings may be helpful in informing clinicians on a patient’s likelihood of discontinuing CZP, based on their baseline characteristics.

Details

Metrics

26 File views/ downloads
36 Record Views
1 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web Of Science research areas
Rheumatology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs from InCites

Logo image